ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 879,88
-0,34%
Dow Jones
44 577,18
0,05%
DAX
21 542,30
0,15%
Brent Oil
74,575
-1,80%
Bitcoin
97 443,48
-0,43%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. RAPT Therapeutics Inc (RAPT)

  7. RAPT Therapeutics Inc (RAPT) Actualités

RAPT

RAPT Therapeutics (RAPT)

RAPT Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RAPT
DateHeureSourceTitreSymboleSociété
28/01/202513h35Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RAPTRAPT Therapeutics Inc
28/01/202506h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RAPTRAPT Therapeutics Inc
21/01/202522h58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RAPTRAPT Therapeutics Inc
13/01/202522h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
09/01/202514h00GlobeNewswire Inc.RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
07/01/202500h38Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RAPTRAPT Therapeutics Inc
06/01/202514h00GlobeNewswire Inc.RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of DirectorsNASDAQ:RAPTRAPT Therapeutics Inc
03/01/202520h08Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RAPTRAPT Therapeutics Inc
23/12/202413h10GlobeNewswire Inc.RAPT Therapeutics Announces $150 Million Private PlacementNASDAQ:RAPTRAPT Therapeutics Inc
23/12/202413h00GlobeNewswire Inc.RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE AntibodyNASDAQ:RAPTRAPT Therapeutics Inc
14/11/202415h39Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
12/11/202414h00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
11/11/202414h00GlobeNewswire Inc.Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver InjuryNASDAQ:RAPTRAPT Therapeutics Inc
08/08/202414h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
08/08/202414h00GlobeNewswire Inc.RAPT Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
24/05/202400h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202414h00GlobeNewswire Inc.RAPT Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
09/04/202418h00GlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202422h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202414h08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
07/03/202414h00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
05/03/202422h30GlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202413h30GlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
14/02/202414h52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
13/02/202414h00GlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
31/01/202414h00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
02/01/202414h00GlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
27/11/202314h00GlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202314h00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202317h00GlobeNewswire Inc.RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCNASDAQ:RAPTRAPT Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RAPT

Dernières Valeurs Consultées

EU
LR
Legrand
EU
BEL20
Bel 20
NASDAQ
AAPL
Apple
EU
DG
Vinci
USI
USTECH100
US Tech 100
SPI
SP500
S&P 500
EU
RNO
Renault
EU
VIV
Vivendi
EU
VK
Vallourec
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
EU
BNP
BNP Paribas
NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
EU
AI
Air Liquide
EU
ML
Michelin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces